



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
08/980,038	11/26/97	KAUFMAN	R 2115001184US

DE ANN F. SMITH
LAHIVE & COCKFIELD, LLP
28 STATE STREET
BOSTON MA 02109

HM12/1011

EXAMINER

CELSA, B

ART UNIT	PAPER NUMBER
1627	24

DATE MAILED: 10/11/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

file copy

Office Action Summary

Application No. 08/980,038	Applicant(s) Kaufman et al.
Examiner Bennett Celso	Group Art Unit 1627

Responsive to communication(s) filed on Jul 20, 2000

This action is FINAL.

Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire three month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

Disposition of Claims

Claim(s) 17-23, 27, 32, 36, and 102-147 is/are pending in the application.

Of the above, claim(s) 18, 19, 32, 36, 102-106, 108, 109, 114-119, and 13 are withdrawn from consideration.

Claim(s) _____ is/are allowed.

Claim(s) 17, 20-23, 27, 107, 110-113, 120, 146, and 147 is/are rejected.

Claim(s) _____ is/are objected to.

Claims _____ are subject to restriction or election requirement.

Application Papers

See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

The drawing(s) filed on _____ is/are objected to by the Examiner.

The proposed drawing correction, filed on _____ is approved disapproved.

The specification is objected to by the Examiner.

The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

All Some* None of the CERTIFIED copies of the priority documents have been

received.

received in Application No. (Series Code/Serial Number) _____.

received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

*Certified copies not received: _____

Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

Notice of References Cited, PTO-892

Information Disclosure Statement(s), PTO-1449, Paper No(s). _____

Interview Summary, PTO-413

Notice of Draftsperson's Patent Drawing Review, PTO-948

Notice of Informal Patent Application, PTO-152

--- SEE OFFICE ACTION ON THE FOLLOWING PAGES ---

Art Unit: 1627

DETAILED ACTION

Continued Prosecution Application

1. The request filed on 7/20/00 in paper no. 23 for a Continued Prosecution Application (CPA) under 37 CFR 1.53(d) based on parent Application No. 08/980,038 is acceptable and a CPA has been established. An action on the CPA follows.
2. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Status of the Claims

Claims 17-23, 27, 32, 36 and 102-147 are currently pending (claims 146 and 147 are newly added)..

Claims 18-19, 32, 36, 102-106, 108-109, 114-119 and 121-145 are withdrawn from consideration as being directed to a nonelected invention.

Claims 17, 20-23, 27, 107, 110-113, 120, 146 and 147 are under consideration.

Outstanding Objection(s) and Rejection(s)

3. Claims 17, 20-23, 27, 107, 110-113, 120, 146 and 147 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

A. In claims 17 and 107, the structure of the human factor FVIII polypeptide which is modified to attain the "procoagulant-active FVIII protein) is indefinite. One needs to know the starting point (e.g. the initial polypeptide structure) in order to determine a final product which would infringe or not infringe the claim. Thus, the metes and bounds of the final protein are not known if the metes and bounds of the starting polypeptide are not described.

Art Unit: 1627

- B. In claims 17 and 107, the term "the B domain" lacks antecedent basis.
- C. In claims 17 and 107, the term "the von Willebrand factor binding site" lacks antecedent basis.
- D. In claims 17 and 107, the term "the A2- and A3- domains" lack antecedent basis.
- E. In claims 17 and 107, the phrase "a mutation at Arg740" lacks metes and bound as to what the metes and bounds of such mutations are. Do mutations include a deletion of Arg740 ? Only substitutions of Arg740 ? A covalent modification of the Arg amino acid (e.g. sidechain, peptide bond, hydrogen)? The nature of the mutation (e.g. natural or man-made) is unclear.
- F. Claim 22, 23, 112, 113, 146 and 147 the phrase "comprises residues 741 to 794 of wild-type factor FVIII..." and "position 794 ... threonine (and leucine) lacks clear antecedent basis since claims 17 and 107 which require deletion of the B-domain which would include these amino acid residues. Additionally, with respect to new claims 146 and 147, "comprising" would encompass the entire B-domain which is contradictory to the claimed absence of the B-domain.

4. Claims 146 and 147 are objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. The phrase "comprises residues 741 to 794 of wild-type factor FVIII..." and "position 794 ... threonine (and leucine)" which include B-domain amino acid residues (up to the entire B-domain) fail to limit claims 17 and 107 that requires deletion of the B-domain. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form.

5. Claims 17, 27, 107 and 120 are rejected under 35 U.S.C. 102(b) as being anticipated by WPIDS English Abstract 88-362113 or EP 295597 (12/88) (which is attached for applicant's convenience).

The EP reference discloses a factor 8 derivative compound and its preparation in pharmaceuticals for treating hemophilia which lacks both the B domain and the vWF binding site (e.g. lacks 741-1689; wherein the B domain is 741-1648 and the vWF binding site is 1649-1689) and which possesses a mutated Arg-740 which acts an amino acid sequence spacer which connects the A1-A2 segment to the C1-C2 segment. The reference further discloses that "the new protein possesses a rapid activation by thrombin aside from a procoagulation activity that is very similar to one of the authentic protein and biologic half-value time" (e.g. see translation at page 2, lines 9-12). Thus the reference protein is stable and possesses a good specific activity. Accordingly, the reference meets the critical chemical claim limitations (e.g. absence of a B domain and Vwf binding site; and presence of a linking amino acid) and possesses improved

Art Unit: 1627

properties and thus would be expected to "inherently" possess the same conformational structure upon thrombin activation as presently claimed. See MPEP 2112.02 and *In re Spada*, 15 USPQ2d 1655,1658 (Fed. Cir. 1990)(“Products of identical chemical composition can not have mutually exclusive properties”). The Examiner lacks the facilities to test the reference protein to see if it meets functional limitations; thus placing the burden directly on applicant (e.g. See *In re Brown*, 173 USPQ 685,688 (CCPA 1972)).

6. Claims 17, 20-22, 27, 107, 110-112, 120, 146 and 147 are rejected under 35 U.S.C. 103(a) as being unpatentable over WPIDS Abstract 88-362113 of EP 295597 (or translation thereof) (12/88) and Kaufman et al., U.S. Pat. No. 5,451,521 (9/95)..

The EP reference discloses a factor 8 derivative compound and pharmaceuticals for treating hemophilia which lacks both the B domain and the vWF binding site (e.g. lacks 741-1689: wherein the B domain is 741-1648 and the vWF binding site is 1649-1689) and which possesses a mutated Arg-740 which acts an amino acid sequence spacer which connects the A1-A2 segment to the C1-C2 segment. The EP reference differs from the presently claimed invention by failing to recite the Arg-740 mutation (e.g. Arg to Ala) and the use of a spacer which comprises a B-domain peptide.

However, the Kaufman reference discloses the making of procoagulant factor VIII derivatives of formula A-X-B wherein A is 1-372 and B is 1690-2332 and X is a linking moiety which may comprise 0-1316 amino acids especially those amino acids selected from the sequence Arg-372 to Ser-1690 with a preferred embodiment incorporating Arg 372-Arg740 (e.g. see col. 8-9). Thus, Kaufman provides motivation to the skilled artisan to attach the A1-A2 heavy chain fragment to the light chain C1-C2 fragment utilizing amino acid linkers derived from the B chain of any length; of which is not critical. The Kaufman reference further teaches the replacement of Arg residues at position 740 (e.g. see Abstract) with non-conservative amino acid substitutions, including Ile, in order to obtain proteolytic resistance (e.g. see col. 2; lines 40-67 and Table II in col. 9). Accordingly, the substitution of Arg 740 with other nonconservative amino acids which possess similar side chain properties to Ile (e.g. aliphatic non-charged e.g. nonpolar), such as alanine or valine would have been obvious to one of ordinary skill in the art who wishes to obtain further proteolytic resistant derivatives. Thus, the modification of the EP reference peptide to incorporate a linking peptide which comprises B-chain residues and the further substitution of Arg with aliphatic non-charged amino acid residues (e.g. Ile, Val or Ala) would have been obvious in view of the teaching of the Kaufman reference to use such modifications in order to make procoagulant proteins.

Accordingly, the EP reference combined with the Kaufman reference render obvious proteins within the scope of the presently claimed invention. Accordingly, the above reference(s)

Art Unit: 1627

meet the critical chemical claim limitations (e.g. absence of a B domain and Vwf binding site; and presence of a linking amino acid) and possesses improved properties and thus would be expected to possess the same conformational structure upon thrombin activation as presently claimed. See MPEP 2112.02 and *In re Spada*, 15 USPQ2d 1655,1658 (Fed. Cir. 1990)(“Products of identical chemical composition can not have mutually exclusive properties”). The Examiner lacks the facilities to test reference protein (s) to see if it meets functional limitations; thus placing the burden directly on applicant (e.g. See *In re Brown*, 173 USPQ 685,688 (CCPA 1972)).

7. Claims 17 and 107 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention (e.g. New Matter Rejection).

Applicant's newly added functional/conformational limitation is clearly broader than that described on page 9, line 6-11 which is limited to thrombin activation, with the further description of the covalent association of the A2 domain with the light chain..

8. This is a CPA of applicant's earlier Application No. 08/980,038. All claims are drawn to the same invention claimed in the earlier application and could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the earlier application. Accordingly, **THIS ACTION IS MADE FINAL** even though it is a first action in this case. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no, however, event will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Art Unit: 1627

General information regarding further correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Celsa whose telephone number is (703) 305-7556.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jyothsna Venkat (art unit 1627), can be reached at (703)308-0570.

Any inquiry of a general nature, or relating to the status of this application, should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Bennett Celsa (art unit 1627)

October 2, 2000

BENNETT CELSA
PRIMARY EXAMINER

